28th Jul 2026 13:36
(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News:
----------
Essentra PLC - Oxford, England-based manufacturer and distributor of plastic-injection-moulded, vinyl-dip-moulded and metal components - Reports revenue of GBP166.1 million for the first half of 2026, up 9.0% or 9.8% at constant currency from GBP152.4 million the previous year. Pretax profit more than doubles, or rises 64% at CER, to GBP3.1 million from GBP1.3 million. Adjusted pretax profit rises 12% to GBP14.0 million from GBP12.5 million. Company declares an interim dividend of 0.9 pence per share, up from 0.8p. Says trading to date is in line with its expectations, and that its guidance for 2026 remains unchanged. "Whilst the group is mindful of the wider geopolitical environment, continued strength in order intake and revenue momentum provide confidence in full year delivery," Essentra says. Adds that it remains confident that it will meet its new medium-term 2028 target for a 14% adjusted operating margin.
----------
Allergy Therapeutics PLC - West Sussex, England-based biotechnology company focused on allergy immunotherapies - Announces the appointment of Helge Weiner-Trapness as executive chair, succeeding Peter Jensen. Weiner-Trapness has been the company's chief strategy officer and an executive director since January, and "brings more than 30 years of experience across leading global investment banks in the US and Asia". He was most recently vice chair of Global Banking at HSBC Holdings PLC. Jensen has been on Allergy Therapeutics' board since 2010 and became chair in 2011. He will stay as a non-executive director "to allow a smooth transition," and will not seek re-election at the next annual general meeting.
----------
Forterra PLC - Northampton, England-based clay and concrete product manufacturer - Announces the appointment of Lisa Oxnard as chief financial officer, having announced on June 11 that outgoing CFO Ben Guyatt will step down and leave Forterra on October 31. Oxnard is currently group financial controller at Genuit Group PLC, and was previously CFO at JELD-WEN Europe and at Doncasters Group Ltd. "She has more than 25 years' international finance and operational leadership experience across listed and private equity-backed manufacturing and industrial businesses, with a strong track record in business transformation, operational improvement, strategic planning and corporate governance," Forterra says. Forterra also reports results for the first half of 2026. Revenue falls 14% to GBP168.8 million from GBP195.1 million the year before, or from GBP186.1 million on a like for like basis. The LFL measure excludes the impact of the Formpave and Bison Bespoke Precast businesses, which closed in the second half of 2025. Pretax profit rises 37% to GBP11.5 million from GBP8.4 million, but adjusted pretax profit falls 13% to GBP14.5 million from GBP16.6 million. Earnings before interest, tax, depreciation and amortisation rises 11% to GBP24.0 million from GBP21.7 million, but adjusted Ebitda falls 9.7% to GBP27.0 million from GBP29.9 million. Adjusted results are before exceptional and adjusting items. Forterra declares interim dividend of 1.7p per share, down 11% from 1.9p. Expects full-year results in line with consensus. Company-compiled analyst consensus is for GBP55.6 million in adjusted Ebitda, with a range of GBP53.1 million to GBP57.6 million. "However, given the current domestic and global geopolitical environment, forecasting demand for our products in H2 remains challenging," Forterra adds.
----------
Biotech Growth Trust PLC - London-based investment trust - argenx SE has agreed as of Monday to acquire Biotech Growth Trust investee Forte Biosciences Inc for approximately USD2.2 billion, or USD77 per share, in cash. Says this represents a 40.5% premium to Forte's closing price on Friday. Notes that "FB102, Forte's lead drug candidate, has recently demonstrated strong proof-of-concept data in two clinical trials for the treatment of vitiligo and coeliac disease," and "could have applications in multiple other autoimmune diseases." Company's holding in Forte represented 3.03% of its net asset value as of Monday. "The investment in Forte was made in November 2024 at USD5.552 per share as part of a confidentially marketed private placement based on the promise of FB102 in coeliac disease," Portfolio Manager Geoff Hsu notes.
----------
Bravura Solutions Ltd - Sydney-based provider of enterprise software for the wealth management and funds industries, which also has a main office in London - Dealings in depositary interests representing its ordinary shares commence on AIM. Company maintains its existing listing on the Australian Securities Exchange. Says the dual London listing broadens its access to capital and to a deeper pool of UK and European institutional investors, and supports the next phase of its growth strategy.
----------
By Emma Curzon, Alliance News reporter
Comments and questions to [email protected]
Copyright 2026 Alliance News Ltd. All Rights Reserved.
Related Shares:
EssentraAllergy Thera.HSBC HoldingsForterraGenuit GroupBiotech GwthBovis Homes